Dose Response Evaluation
- 8 Downloads
This paper suggests that pharmacokinetic data might provide a rational basis to improve dose-response trials. Construction of plasma concentration confidence intervals may be a tool to predict optimal drug dose ratios for dose-response studies and, for some drugs, may point to the need for plasma concentration measurement in clinical practice. An important task now is to integrate pharmacokinetic knowledge into the design of clinical trials. To facilitate this, studies on clinical pharmacokinetics should report individual plasma AUC or clearance values or give the 95% confidence intervals of the observation.
KeywordsAdvanced Breast Cancer Plasma Drug Concentration Medroxyprogesterone Acetate Aminoglutethimide Sponse Rate
Unable to display preview. Download preview PDF.
- Glantz SA. Primer of biostatistics, 2nd ed., McGraw-Hill Book Company, New York, 1987Google Scholar
- Hodges JL, Lehmann EL. Basic concepts of probability and statistics, Holden Day Inc., San Francisco, 1970Google Scholar
- Johnson RA, Wichern DW. Applied multivariate analysis, Prentice-Hall Inc., Englewood Cliffs, NJ, 1982Google Scholar
- Lindgren BW. Statistical theory, MacMillan Company, London, 1962Google Scholar
- Lønning PE. Aromatse inhibition: past, present and future. In Dousett M (Ed.) Endocrine aspects of breast cancer, pp. 53–75, Parthenon Publishing Group, Carnforth, 1992Google Scholar
- Robustelli della Cuna G. 500mg versus 1000mg aminoglutethimide (AG) in advanced breast cancer: 3 years results of an Italian multicentre trial. European Journal of Cancer 27 (Suppl. 2): s69, 1991Google Scholar
- Rosner B. Fundamentals of biostatistics, Duxbury Press, Boston, 1982Google Scholar
- Simon RM. Design and conduct of clinical trials. In DeVita Jr VT et al. (Eds) Cancer — principles and practice of oncology, pp. 329–350, J.B. Lippincott Company, Philadelphia, 1985Google Scholar
- Spiegel MR. Probability and statistics, McGraw-Hill Book Company, New York, 1975Google Scholar